[Form 4] Aspira Women's Health Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.

Positive

• Director purchase disclosed: 55,556 common shares acquired at $0.45 on 09/17/2025.
• Warrants acquired: 41,667 warrants exercisable 09/17/2025 and expiring 09/17/2030, each underlying one share.
• Increased reported ownership: 375,697 shares indirectly via HealthView Asset Management and 60,913 indirectly by spouse.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director bought common stock and warrants, increasing indirect holdings; modestly positive signal but limited by size.

The Form 4 documents a purchase of 55,556 common shares at $0.45 and acquisition of 41,667 warrants exercisable now through 09/17/2030. The transactions increased indirect beneficial ownership to 375,697 shares via HealthView Asset Management and 60,913 shares via spouse. For investors, insider purchases can indicate confidence, but the filing lacks context on total outstanding shares or proportionate ownership, limiting assessment of materiality.

Corporate Governance Expert

TL;DR: Transaction is properly disclosed and signed; timing and structure (direct, indirect, spouse) are clearly reported.

The Form 4 appears complete: it identifies reporting person, relationship as Director, transaction codes, prices, and ownership form (indirect/direct). The filing includes the signature and date. The report separates holdings attributed to an investment vehicle and spouse, which is helpful for governance transparency. No amendments or additional explanatory notes accompany the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

cohen Jeffrey k

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		P		55,556	A	$0.45	375,697	I	By HealthView Asset Management
Common Stock								60,913	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$0.75	09/17/2025		P		41,667		09/17/2025	09/17/2030	Common Stock, par value $0.001	41,667	$0	491,985	D

Explanation of Responses:

	/s/ Jeffrey Cohen	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeffrey K. Cohen report on Form 4 for AWHL?

He reported acquiring 55,556 common shares at $0.45 and 41,667 warrants on 09/17/2025; ownership figures are listed in the filing.

How many shares does Jeffrey Cohen beneficially own after the transactions?

The filing reports 375,697 shares indirectly via HealthView Asset Management and 60,913 indirectly by spouse following the transactions.

What are the terms of the warrants acquired in the Form 4?

41,667 warrants with an exercise/conversion price of $0.75, exercisable 09/17/2025 and expiring 09/17/2030, underlying 41,667 common shares.

When were the transactions executed and when was the Form 4 signed?

Transactions executed on 09/17/2025; the Form 4 is signed by Jeffrey Cohen on 09/18/2025.

What is Jeffrey Cohen's relationship to Aspira Women's Health listed on the Form 4?

He is listed as a Director of Aspira Women's Health Inc.